English

Agios Pharmaceuticals, Inc.

EDGAR

AGIO Filing (144) · filed 2026-10-26

Annual consolidated revenue for 2025: about USD 54.03M, using the latest reported figures. The previous period, 2024, was about USD 36.5M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

44.7 million USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 44745000 USD Source

Operating margin

-247.07%

2026 Q2 · %

Exact inputs and evidence

Operating Income: -110552000 USD Source
Revenue: 44745000 USD Source

Operating cash flow

-57.3 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -176232000 USD Source
Operating Cash Flow: -118920000 USD Source

Free cash flow

-58.5 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -176232000 USD Source
Operating Cash Flow: -118920000 USD Source
Capital Expenditure: 1981000 USD Source
Capital Expenditure: 769000 USD Source

Cash and cash equivalents: 99.6 million USD 2026-06-30 Source
Exact value

99647000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 59.6 million shares 2026-06-30 Source
Exact value

59604830 shares

Reported share-count change

2.70% · 1.57 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

58038545 shares · 2025-06-30· Source
59604830 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

98.3 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 12880000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 54028000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 34061000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 20746000 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 44745000 USD · 2026-04-01 – 2026-06-30 Source

Net income

-411 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -103433000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -412781000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -304742000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -99111000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -100703000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-361 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -276764000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -188613000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -372977000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -276764000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -118920000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -176232000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -118920000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

4.66 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 3196000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1641000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 4316000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 3196000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 769000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 1981000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 769000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-365 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -276764000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -188613000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -372977000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -276764000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -118920000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -176232000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -118920000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 3196000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1641000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 4316000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 3196000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 769000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 1981000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 769000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-26.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2025-12-31
Operating income: 11 of 11 periods available· newest 2025-12-31
Net income: 11 of 11 periods available· newest 2025-12-31
Operating cash flow: 11 of 11 periods available· newest 2025-12-31
Capital expenditure: 11 of 11 periods available· newest 2025-12-31
Total assets: 11 of 11 periods available· newest 2025-12-31
Total liabilities: 10 of 11 periods available· newest 2025-12-31
Current assets: 11 of 11 periods available· newest 2025-12-31
Current liabilities: 11 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 11 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+48%

Prior period

USD 36.5 million

2024-01-01 – 2024-12-31
Current period

USD 54.03 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

54028000 − 36498000 = 17530000 USD

36498000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
54028000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Agios Pharmaceuticals, Inc. · 2025-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Year-over-year change in Revenue: 17530000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 54028000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1241342 Filing: 000143922226000025 Input fundies:Revenue: 36498000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1242024 Filing: 000143922226000025
The citation records this snapshot. The page link may show a newer release later.
Net income
-161.3%

Prior period

USD 673.73 million

2024-01-01 – 2024-12-31
Current period

−USD 412.78 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-412781000 − 673725000 = -1086506000 USD

673725000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-412781000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Agios Pharmaceuticals, Inc. · 2025-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Year-over-year change in Net income: -1086506000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -412781000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1382882 Filing: 000143922226000025 Input fundies:NetIncome: 673725000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1383653 Filing: 000143922226000025
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 16.86 million

Prior period

−USD 389.84 million

2024-01-01 – 2024-12-31
Current period

−USD 372.98 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-372977000 − -389841000 = 16864000 USD

-389841000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-372977000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Agios Pharmaceuticals, Inc. · 2025-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Year-over-year change in Operating cash flow: 16864000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -372977000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1421148 Filing: 000143922226000025 Input fundies:OperatingCashFlow: -389841000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1421826 Filing: 000143922226000025
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+156.1%

Prior period

USD 1.69 million

2024-01-01 – 2024-12-31
Current period

USD 4.32 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

4316000 − 1685000 = 2631000 USD

1685000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
4316000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Agios Pharmaceuticals, Inc. · 2025-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Year-over-year change in Capital expenditure: 2631000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 4316000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1434038 Filing: 000143922226000025 Input fundies:CapitalExpenditure: 1685000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1434627 Filing: 000143922226000025
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 54.03 million 100% of revenue
Cost of revenue USD 6.35 million 12% of revenue
Operating expenses USD 519.82 million 962% of revenue
Operating income −USD 472.13 million −874% of revenue
Tax, interest and other Derived −USD 59.35 million −110% of revenue
Net income −USD 412.78 million −764% of revenue

Cash

Operating cash flow −USD 372.98 million −690% of revenue
Capital expenditure USD 4.32 million 8% of revenue
Free cash flow Derived −USD 377.29 million −698% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Operating loss: operating costs were 388% of revenue.
2017 Operating loss: operating costs were 846% of revenue.
2018 Operating loss: operating costs were 484% of revenue.
2019 Operating loss: operating costs were 368% of revenue.
2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Operating loss: operating costs were 2,832% of revenue.
2023 Operating loss: operating costs were 1,560% of revenue.
2024 Operating loss: operating costs were 1,266% of revenue.
2025 Operating loss: operating costs were 974% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	69892000	270877000 Derived	-200985000	-2514000 Derived	-198471000	28647000 Derived	Source 2016-01-01 – 2016-12-31: 69892000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -200985000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -198471000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: 38562000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 9915000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	43011000	363805000 Derived	-320794000	-6124000 Derived	-314670000	-289859000 Derived	Source 2017-01-01 – 2017-12-31: 43011000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -320794000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -314670000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -285232000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 4627000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	94387000	456866000 Derived	-362479000	-16451000 Derived	-346028000	-311407000 Derived	Source 2018-01-01 – 2018-12-31: 94387000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -362479000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -346028000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -304421000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 6986000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	117912000	434181000 Derived	-316269000	95203000 Derived	-411472000	-382650000 Derived	Source 2019-01-01 – 2019-12-31: 117912000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -316269000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -411472000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -370622000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 12028000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	0	335916000 Derived	-335916000	-8546000 Derived	-327370000	-304865000 Derived	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -335916000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -327370000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -290759000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 14106000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	0	378418000 Derived	-378418000	-1983133000 Derived	1604715000	-413061000 Derived	Source 2021-01-01 – 2021-12-31: 0 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -378418000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: 1604715000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -407320000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 5741000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	14240000	403287000 Derived	-389047000	-157246000 Derived	-231801000	-314359000 Derived	Source 2022-01-01 – 2022-12-31: 14240000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -389047000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -231801000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -309478000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 4881000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	26823000	418310000 Derived	-391487000	-39399000 Derived	-352088000	-297061000 Derived	Source 2023-01-01 – 2023-12-31: 26823000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -391487000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -352088000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -296062000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 999000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	36498000	462235000 Derived	-425737000	-1099462000 Derived	673725000	-391526000 Derived	Source 2024-01-01 – 2024-12-31: 36498000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -425737000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: 673725000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -389841000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 1685000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	54028000	526160000 Derived	-472132000	-59351000 Derived	-412781000	-377293000 Derived	Source 2025-01-01 – 2025-12-31: 54028000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -472132000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -412781000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -372977000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 4316000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 54M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Revenue	69892000	Revenue: 69892000 Open source
20172017-12-31	Revenue	43011000	Revenue: 43011000 Open source
20182018-12-31	Revenue	94387000	Revenue: 94387000 Open source
20192019-12-31	Revenue	117912000	Revenue: 117912000 Open source
20202020-12-31	Revenue	0	Revenue: 0 Open source
20212021-12-31	Revenue	0	Revenue: 0 Open source
20222022-12-31	Revenue	14240000	Revenue: 14240000 Open source
20232023-12-31	Revenue	26823000	Revenue: 26823000 Open source
20242024-12-31	Revenue	36498000	Revenue: 36498000 Open source
20252025-12-31	Revenue	54028000	Revenue: 54028000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

48% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	18.2%	Revenue: 69892000 Open source Revenue: 59119000 Open source
20172017-12-31	Year over year	-38.5%	Revenue: 43011000 Open source Revenue: 69892000 Open source
20182018-12-31	Year over year	119.4%	Revenue: 94387000 Open source Revenue: 43011000 Open source
20192019-12-31	Year over year	24.9%	Revenue: 117912000 Open source Revenue: 94387000 Open source
20202020-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 117912000 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20222022-12-31	Year over year	No prior comparable period	Revenue: 14240000 Open source Revenue: 0 Open source
20232023-12-31	Year over year	88.4%	Revenue: 26823000 Open source Revenue: 14240000 Open source
20242024-12-31	Year over year	36.1%	Revenue: 36498000 Open source Revenue: 26823000 Open source
20252025-12-31	Year over year	48%	Revenue: 54028000 Open source Revenue: 36498000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -873.9% 2025

Net margin -764% 2025

Free cash flow margin -698.3% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	-287.6%	Operating Income: -200985000 Open source Revenue: 69892000 Open source
20172017-12-31	Operating margin	-745.8%	Operating Income: -320794000 Open source Revenue: 43011000 Open source
20182018-12-31	Operating margin	-384%	Operating Income: -362479000 Open source Revenue: 94387000 Open source
20192019-12-31	Operating margin	-268.2%	Operating Income: -316269000 Open source Revenue: 117912000 Open source
20202020-12-31	Operating margin	Not reported	Operating Income: -335916000 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	Not reported	Operating Income: -378418000 Open source Revenue: 0 Open source
20222022-12-31	Operating margin	-2,732.1%	Operating Income: -389047000 Open source Revenue: 14240000 Open source
20232023-12-31	Operating margin	-1,459.5%	Operating Income: -391487000 Open source Revenue: 26823000 Open source
20242024-12-31	Operating margin	-1,166.5%	Operating Income: -425737000 Open source Revenue: 36498000 Open source
20252025-12-31	Operating margin	-873.9%	Operating Income: -472132000 Open source Revenue: 54028000 Open source
20162016-12-31	Net margin	-284%	Net Income: -198471000 Open source Revenue: 69892000 Open source
20172017-12-31	Net margin	-731.6%	Net Income: -314670000 Open source Revenue: 43011000 Open source
20182018-12-31	Net margin	-366.6%	Net Income: -346028000 Open source Revenue: 94387000 Open source
20192019-12-31	Net margin	-349%	Net Income: -411472000 Open source Revenue: 117912000 Open source
20202020-12-31	Net margin	Not reported	Net Income: -327370000 Open source Revenue: 0 Open source
20212021-12-31	Net margin	Not reported	Net Income: 1604715000 Open source Revenue: 0 Open source
20222022-12-31	Net margin	-1,627.8%	Net Income: -231801000 Open source Revenue: 14240000 Open source
20232023-12-31	Net margin	-1,312.6%	Net Income: -352088000 Open source Revenue: 26823000 Open source
20242024-12-31	Net margin	1,845.9%	Net Income: 673725000 Open source Revenue: 36498000 Open source
20252025-12-31	Net margin	-764%	Net Income: -412781000 Open source Revenue: 54028000 Open source
20162016-12-31	Free cash flow margin	41%	Revenue: 69892000 Open source Operating Cash Flow: 38562000 Open source Capital Expenditure: 9915000 Open source
20172017-12-31	Free cash flow margin	-673.9%	Revenue: 43011000 Open source Operating Cash Flow: -285232000 Open source Capital Expenditure: 4627000 Open source
20182018-12-31	Free cash flow margin	-329.9%	Revenue: 94387000 Open source Operating Cash Flow: -304421000 Open source Capital Expenditure: 6986000 Open source
20192019-12-31	Free cash flow margin	-324.5%	Revenue: 117912000 Open source Operating Cash Flow: -370622000 Open source Capital Expenditure: 12028000 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -290759000 Open source Capital Expenditure: 14106000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -407320000 Open source Capital Expenditure: 5741000 Open source
20222022-12-31	Free cash flow margin	-2,207.6%	Revenue: 14240000 Open source Operating Cash Flow: -309478000 Open source Capital Expenditure: 4881000 Open source
20232023-12-31	Free cash flow margin	-1,107.5%	Revenue: 26823000 Open source Operating Cash Flow: -296062000 Open source Capital Expenditure: 999000 Open source
20242024-12-31	Free cash flow margin	-1,072.7%	Revenue: 36498000 Open source Operating Cash Flow: -389841000 Open source Capital Expenditure: 1685000 Open source
20252025-12-31	Free cash flow margin	-698.3%	Revenue: 54028000 Open source Operating Cash Flow: -372977000 Open source Capital Expenditure: 4316000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -373M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	38562000	Operating Cash Flow: 38562000 Open source
20172017-12-31	Operating cash flow	-285232000	Operating Cash Flow: -285232000 Open source
20182018-12-31	Operating cash flow	-304421000	Operating Cash Flow: -304421000 Open source
20192019-12-31	Operating cash flow	-370622000	Operating Cash Flow: -370622000 Open source
20202020-12-31	Operating cash flow	-290759000	Operating Cash Flow: -290759000 Open source
20212021-12-31	Operating cash flow	-407320000	Operating Cash Flow: -407320000 Open source
20222022-12-31	Operating cash flow	-309478000	Operating Cash Flow: -309478000 Open source
20232023-12-31	Operating cash flow	-296062000	Operating Cash Flow: -296062000 Open source
20242024-12-31	Operating cash flow	-389841000	Operating Cash Flow: -389841000 Open source
20252025-12-31	Operating cash flow	-372977000	Operating Cash Flow: -372977000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -377.3M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	28647000	Operating Cash Flow: 38562000 Open source Capital Expenditure: 9915000 Open source
20172017-12-31	Free cash flow	-289859000	Operating Cash Flow: -285232000 Open source Capital Expenditure: 4627000 Open source
20182018-12-31	Free cash flow	-311407000	Operating Cash Flow: -304421000 Open source Capital Expenditure: 6986000 Open source
20192019-12-31	Free cash flow	-382650000	Operating Cash Flow: -370622000 Open source Capital Expenditure: 12028000 Open source
20202020-12-31	Free cash flow	-304865000	Operating Cash Flow: -290759000 Open source Capital Expenditure: 14106000 Open source
20212021-12-31	Free cash flow	-413061000	Operating Cash Flow: -407320000 Open source Capital Expenditure: 5741000 Open source
20222022-12-31	Free cash flow	-314359000	Operating Cash Flow: -309478000 Open source Capital Expenditure: 4881000 Open source
20232023-12-31	Free cash flow	-297061000	Operating Cash Flow: -296062000 Open source Capital Expenditure: 999000 Open source
20242024-12-31	Free cash flow	-391526000	Operating Cash Flow: -389841000 Open source Capital Expenditure: 1685000 Open source
20252025-12-31	Free cash flow	-377293000	Operating Cash Flow: -372977000 Open source Capital Expenditure: 4316000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

8% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	42.1%	Total Liabilities: 260503000 Open source Total Assets: 619094000 Open source
20172017-12-31	Liabilities / assets	38.9%	Total Liabilities: 238894000 Open source Total Assets: 614397000 Open source
20182018-12-31	Liabilities / assets	19.9%	Total Liabilities: 170920000 Open source Total Assets: 858457000 Open source
20192019-12-31	Liabilities / assets	28.1%	Total Liabilities: 250213000 Open source Total Assets: 890741000 Open source
20202020-12-31	Liabilities / assets	53.2%	Total Liabilities: 453452000 Open source Total Assets: 852952000 Open source
20212021-12-31	Liabilities / assets	10.1%	Total Liabilities: 145761000 Open source Total Assets: 1437736000 Open source
20222022-12-31	Liabilities / assets	11.1%	Total Liabilities: 137904000 Open source Total Assets: 1238718000 Open source
20232023-12-31	Liabilities / assets	13.5%	Total Liabilities: 126099000 Open source Total Assets: 937118000 Open source
20242024-12-31	Liabilities / assets	7.3%	Total Liabilities: 122243000 Open source Total Assets: 1663199000 Open source
20252025-12-31	Liabilities / assets	8%	Total Liabilities: 104111000 Open source Total Assets: 1297225000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

11.46× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	6.33×	Current Assets: 559892000 Open source Current Liabilities: 88433000 Open source
20172017-12-31	Current assets / current liabilities	4.69×	Current Assets: 445261000 Open source Current Liabilities: 94941000 Open source
20182018-12-31	Current assets / current liabilities	6.56×	Current Assets: 613780000 Open source Current Liabilities: 93503000 Open source
20192019-12-31	Current assets / current liabilities	6.59×	Current Assets: 611704000 Open source Current Liabilities: 92886000 Open source
20202020-12-31	Current assets / current liabilities	6.74×	Current Assets: 636677000 Open source Current Liabilities: 94394000 Open source
20212021-12-31	Current assets / current liabilities	17.79×	Current Assets: 1064231000 Open source Current Liabilities: 59826000 Open source
20222022-12-31	Current assets / current liabilities	13.3×	Current Assets: 832772000 Open source Current Liabilities: 62629000 Open source
20232023-12-31	Current assets / current liabilities	12.27×	Current Assets: 833835000 Open source Current Liabilities: 67955000 Open source
20242024-12-31	Current assets / current liabilities	11.9×	Current Assets: 965600000 Open source Current Liabilities: 81156000 Open source
20252025-12-31	Current assets / current liabilities	11.46×	Current Assets: 942052000 Open source Current Liabilities: 82206000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 198.47 million Exact value Exact value: -198471000 USD 2016-01-01 – 2016-12-31: -198471000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Agios Pharmaceuticals, Inc. · 2016-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Net Income: -198471000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -198471000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922219000004/agio-20181231.htm#1951750 Filing: 000143922219000004 The citation records this snapshot. The page link may show a newer release later.	USD 38.56 million Exact value Exact value: 38562000 USD 2016-01-01 – 2016-12-31: 38562000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Agios Pharmaceuticals, Inc. · 2016-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Operating Cash Flow: 38562000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 38562000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922219000004/agio-20181231.htm#2007251 Filing: 000143922219000004 The citation records this snapshot. The page link may show a newer release later.	USD 9.92 million Exact value Exact value: 9915000 USD 2016-01-01 – 2016-12-31: 9915000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Agios Pharmaceuticals, Inc. · 2016-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Capital Expenditure: 9915000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9915000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922219000004/agio-20181231.htm#2019377 Filing: 000143922219000004 The citation records this snapshot. The page link may show a newer release later.	USD 28.65 million Calculation and evidence 38562000 − 9915000 USD Exact free cash flow: 28647000 USD 2016-01-01 – 2016-12-31: 38562000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 9915000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Agios Pharmaceuticals, Inc. · 2016-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Free cash flow: 28647000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 38562000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922219000004/agio-20181231.htm#2007251 Filing: 000143922219000004 Input fundies:CapitalExpenditure: 9915000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922219000004/agio-20181231.htm#2019377 Filing: 000143922219000004 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 314.67 million Exact value Exact value: -314670000 USD 2017-01-01 – 2017-12-31: -314670000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Agios Pharmaceuticals, Inc. · 2017-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Net Income: -314670000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -314670000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922220000014/agio-20191231.htm#2069352 Filing: 000143922220000014 The citation records this snapshot. The page link may show a newer release later.	−USD 285.23 million Exact value Exact value: -285232000 USD 2017-01-01 – 2017-12-31: -285232000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Agios Pharmaceuticals, Inc. · 2017-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Operating Cash Flow: -285232000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -285232000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922220000014/agio-20191231.htm#2141874 Filing: 000143922220000014 The citation records this snapshot. The page link may show a newer release later.	USD 4.63 million Exact value Exact value: 4627000 USD 2017-01-01 – 2017-12-31: 4627000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Agios Pharmaceuticals, Inc. · 2017-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Capital Expenditure: 4627000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4627000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922220000014/agio-20191231.htm#2155474 Filing: 000143922220000014 The citation records this snapshot. The page link may show a newer release later.	−USD 289.86 million Calculation and evidence -285232000 − 4627000 USD Exact free cash flow: -289859000 USD 2017-01-01 – 2017-12-31: -285232000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 4627000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Agios Pharmaceuticals, Inc. · 2017-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Free cash flow: -289859000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -285232000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922220000014/agio-20191231.htm#2141874 Filing: 000143922220000014 Input fundies:CapitalExpenditure: 4627000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922220000014/agio-20191231.htm#2155474 Filing: 000143922220000014 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 346.03 million Exact value Exact value: -346028000 USD 2018-01-01 – 2018-12-31: -346028000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Agios Pharmaceuticals, Inc. · 2018-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Net Income: -346028000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -346028000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922221000029/agio-20201231.htm#1995818 Filing: 000143922221000029 The citation records this snapshot. The page link may show a newer release later.	−USD 304.42 million Exact value Exact value: -304421000 USD 2018-01-01 – 2018-12-31: -304421000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Agios Pharmaceuticals, Inc. · 2018-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Operating Cash Flow: -304421000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -304421000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922221000029/agio-20201231.htm#1743053 Filing: 000143922221000029 The citation records this snapshot. The page link may show a newer release later.	USD 6.99 million Exact value Exact value: 6986000 USD 2018-01-01 – 2018-12-31: 6986000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Agios Pharmaceuticals, Inc. · 2018-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Capital Expenditure: 6986000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6986000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922221000029/agio-20201231.htm#1753387 Filing: 000143922221000029 The citation records this snapshot. The page link may show a newer release later.	−USD 311.41 million Calculation and evidence -304421000 − 6986000 USD Exact free cash flow: -311407000 USD 2018-01-01 – 2018-12-31: -304421000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 6986000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Agios Pharmaceuticals, Inc. · 2018-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Free cash flow: -311407000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -304421000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922221000029/agio-20201231.htm#1743053 Filing: 000143922221000029 Input fundies:CapitalExpenditure: 6986000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922221000029/agio-20201231.htm#1753387 Filing: 000143922221000029 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 411.47 million Exact value Exact value: -411472000 USD 2019-01-01 – 2019-12-31: -411472000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Agios Pharmaceuticals, Inc. · 2019-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Net Income: -411472000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -411472000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922222000024/agio-20211231.htm#1422299 Filing: 000143922222000024 The citation records this snapshot. The page link may show a newer release later.	−USD 370.62 million Exact value Exact value: -370622000 USD 2019-01-01 – 2019-12-31: -370622000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Agios Pharmaceuticals, Inc. · 2019-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Operating Cash Flow: -370622000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -370622000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922222000024/agio-20211231.htm#1474219 Filing: 000143922222000024 The citation records this snapshot. The page link may show a newer release later.	USD 12.03 million Exact value Exact value: 12028000 USD 2019-01-01 – 2019-12-31: 12028000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Agios Pharmaceuticals, Inc. · 2019-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Capital Expenditure: 12028000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 12028000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922222000024/agio-20211231.htm#1484589 Filing: 000143922222000024 The citation records this snapshot. The page link may show a newer release later.	−USD 382.65 million Calculation and evidence -370622000 − 12028000 USD Exact free cash flow: -382650000 USD 2019-01-01 – 2019-12-31: -370622000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 12028000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Agios Pharmaceuticals, Inc. · 2019-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Free cash flow: -382650000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -370622000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922222000024/agio-20211231.htm#1474219 Filing: 000143922222000024 Input fundies:CapitalExpenditure: 12028000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922222000024/agio-20211231.htm#1484589 Filing: 000143922222000024 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 327.37 million Exact value Exact value: -327370000 USD 2020-01-01 – 2020-12-31: -327370000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Agios Pharmaceuticals, Inc. · 2020-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Net Income: -327370000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -327370000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000039/agio-20221231.htm#1469955 Filing: 000143922223000039 The citation records this snapshot. The page link may show a newer release later.	−USD 290.76 million Exact value Exact value: -290759000 USD 2020-01-01 – 2020-12-31: -290759000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Agios Pharmaceuticals, Inc. · 2020-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Operating Cash Flow: -290759000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -290759000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000039/agio-20221231.htm#1534020 Filing: 000143922223000039 The citation records this snapshot. The page link may show a newer release later.	USD 14.11 million Exact value Exact value: 14106000 USD 2020-01-01 – 2020-12-31: 14106000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Agios Pharmaceuticals, Inc. · 2020-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Capital Expenditure: 14106000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 14106000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000039/agio-20221231.htm#1547588 Filing: 000143922223000039 The citation records this snapshot. The page link may show a newer release later.	−USD 304.87 million Calculation and evidence -290759000 − 14106000 USD Exact free cash flow: -304865000 USD 2020-01-01 – 2020-12-31: -290759000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 14106000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Agios Pharmaceuticals, Inc. · 2020-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Free cash flow: -304865000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -290759000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000039/agio-20221231.htm#1534020 Filing: 000143922223000039 Input fundies:CapitalExpenditure: 14106000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000039/agio-20221231.htm#1547588 Filing: 000143922223000039 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	USD 1.6 billion Exact value Exact value: 1604715000 USD 2021-01-01 – 2021-12-31: 1604715000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Agios Pharmaceuticals, Inc. · 2021-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Net Income: 1604715000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: 1604715000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922224000035/agio-20231231.htm#1384515 Filing: 000143922224000035 The citation records this snapshot. The page link may show a newer release later.	−USD 407.32 million Exact value Exact value: -407320000 USD 2021-01-01 – 2021-12-31: -407320000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Agios Pharmaceuticals, Inc. · 2021-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Operating Cash Flow: -407320000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -407320000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922224000035/agio-20231231.htm#1429502 Filing: 000143922224000035 The citation records this snapshot. The page link may show a newer release later.	USD 5.74 million Exact value Exact value: 5741000 USD 2021-01-01 – 2021-12-31: 5741000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Agios Pharmaceuticals, Inc. · 2021-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Capital Expenditure: 5741000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 5741000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922224000035/agio-20231231.htm#1440296 Filing: 000143922224000035 The citation records this snapshot. The page link may show a newer release later.	−USD 413.06 million Calculation and evidence -407320000 − 5741000 USD Exact free cash flow: -413061000 USD 2021-01-01 – 2021-12-31: -407320000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 5741000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Agios Pharmaceuticals, Inc. · 2021-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Free cash flow: -413061000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -407320000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922224000035/agio-20231231.htm#1429502 Filing: 000143922224000035 Input fundies:CapitalExpenditure: 5741000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922224000035/agio-20231231.htm#1440296 Filing: 000143922224000035 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 231.8 million Exact value Exact value: -231801000 USD 2022-01-01 – 2022-12-31: -231801000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Agios Pharmaceuticals, Inc. · 2022-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Net Income: -231801000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -231801000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000009/agio-20241231.htm#1393731 Filing: 000143922225000009 The citation records this snapshot. The page link may show a newer release later.	−USD 309.48 million Exact value Exact value: -309478000 USD 2022-01-01 – 2022-12-31: -309478000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Agios Pharmaceuticals, Inc. · 2022-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Operating Cash Flow: -309478000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -309478000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000009/agio-20241231.htm#1433930 Filing: 000143922225000009 The citation records this snapshot. The page link may show a newer release later.	USD 4.88 million Exact value Exact value: 4881000 USD 2022-01-01 – 2022-12-31: 4881000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Agios Pharmaceuticals, Inc. · 2022-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Capital Expenditure: 4881000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4881000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000009/agio-20241231.htm#1446743 Filing: 000143922225000009 The citation records this snapshot. The page link may show a newer release later.	−USD 314.36 million Calculation and evidence -309478000 − 4881000 USD Exact free cash flow: -314359000 USD 2022-01-01 – 2022-12-31: -309478000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 4881000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Agios Pharmaceuticals, Inc. · 2022-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Free cash flow: -314359000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -309478000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000009/agio-20241231.htm#1433930 Filing: 000143922225000009 Input fundies:CapitalExpenditure: 4881000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922225000009/agio-20241231.htm#1446743 Filing: 000143922225000009 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 352.09 million Exact value Exact value: -352088000 USD 2023-01-01 – 2023-12-31: -352088000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Agios Pharmaceuticals, Inc. · 2023-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Net Income: -352088000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -352088000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1384422 Filing: 000143922226000025 The citation records this snapshot. The page link may show a newer release later.	−USD 296.06 million Exact value Exact value: -296062000 USD 2023-01-01 – 2023-12-31: -296062000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Agios Pharmaceuticals, Inc. · 2023-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Operating Cash Flow: -296062000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -296062000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1422505 Filing: 000143922226000025 The citation records this snapshot. The page link may show a newer release later.	USD 999,000 Exact value Exact value: 999000 USD 2023-01-01 – 2023-12-31: 999000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Agios Pharmaceuticals, Inc. · 2023-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Capital Expenditure: 999000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 999000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1435217 Filing: 000143922226000025 The citation records this snapshot. The page link may show a newer release later.	−USD 297.06 million Calculation and evidence -296062000 − 999000 USD Exact free cash flow: -297061000 USD 2023-01-01 – 2023-12-31: -296062000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 999000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Agios Pharmaceuticals, Inc. · 2023-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Free cash flow: -297061000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -296062000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1422505 Filing: 000143922226000025 Input fundies:CapitalExpenditure: 999000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1435217 Filing: 000143922226000025 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	USD 673.73 million Exact value Exact value: 673725000 USD 2024-01-01 – 2024-12-31: 673725000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Agios Pharmaceuticals, Inc. · 2024-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Net Income: 673725000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: 673725000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1383653 Filing: 000143922226000025 The citation records this snapshot. The page link may show a newer release later.	−USD 389.84 million Exact value Exact value: -389841000 USD 2024-01-01 – 2024-12-31: -389841000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Agios Pharmaceuticals, Inc. · 2024-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Operating Cash Flow: -389841000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -389841000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1421826 Filing: 000143922226000025 The citation records this snapshot. The page link may show a newer release later.	USD 1.69 million Exact value Exact value: 1685000 USD 2024-01-01 – 2024-12-31: 1685000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Agios Pharmaceuticals, Inc. · 2024-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Capital Expenditure: 1685000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1685000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1434627 Filing: 000143922226000025 The citation records this snapshot. The page link may show a newer release later.	−USD 391.53 million Calculation and evidence -389841000 − 1685000 USD Exact free cash flow: -391526000 USD 2024-01-01 – 2024-12-31: -389841000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 1685000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Agios Pharmaceuticals, Inc. · 2024-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Free cash flow: -391526000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -389841000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1421826 Filing: 000143922226000025 Input fundies:CapitalExpenditure: 1685000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1434627 Filing: 000143922226000025 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 412.78 million Exact value Exact value: -412781000 USD 2025-01-01 – 2025-12-31: -412781000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Agios Pharmaceuticals, Inc. · 2025-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Net Income: -412781000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -412781000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1382882 Filing: 000143922226000025 The citation records this snapshot. The page link may show a newer release later.	−USD 372.98 million Exact value Exact value: -372977000 USD 2025-01-01 – 2025-12-31: -372977000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Agios Pharmaceuticals, Inc. · 2025-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Operating Cash Flow: -372977000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -372977000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1421148 Filing: 000143922226000025 The citation records this snapshot. The page link may show a newer release later.	USD 4.32 million Exact value Exact value: 4316000 USD 2025-01-01 – 2025-12-31: 4316000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Agios Pharmaceuticals, Inc. · 2025-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Capital Expenditure: 4316000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 4316000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1434038 Filing: 000143922226000025 The citation records this snapshot. The page link may show a newer release later.	−USD 377.29 million Calculation and evidence -372977000 − 4316000 USD Exact free cash flow: -377293000 USD 2025-01-01 – 2025-12-31: -372977000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 4316000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Agios Pharmaceuticals, Inc. · 2025-12-31 Agios Pharmaceuticals, Inc. (edgar:1439222) Free cash flow: -377293000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T07:45:36Z Snapshot: 965d01d08573aedac3f27ef3421e625479fdbf9a04731878e81b58a6c96bf1e5 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1439222?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -372977000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1421148 Filing: 000143922226000025 Input fundies:CapitalExpenditure: 4316000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1439222/000143922226000025/agio-20251231.htm#1434038 Filing: 000143922226000025 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

245 filings · 3,644 latest values · 3,647 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001439222, 1439222, AGIO, edgar:1439222

Also known as AGIOS PHARMACEUTICALS INC, AGIOS PHARMACEUTICALS, INC., Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation